<?xml version="1.0" encoding="UTF-8"?>
<p>Maertens et al. used maribavir (dose-blinded) to treat cytomegalovirus reactivation preemptively for recipients of hematopoietic cell or solid organ transplants (SOT) (â‰¥18 years old) with CMV reactivation in a phase II and open-label clinical trial [
 <xref rid="B46-viruses-12-00021" ref-type="bibr">46</xref>]. The results showed that maribavir at a dose of at least 400 mg twice daily had efficacy like that of valganciclovir for removing CMV viremia. Though a higher incidence of gastrointestinal adverse events were found in the maribavir -treated group, the neutropenia incidence was lower [
 <xref rid="B46-viruses-12-00021" ref-type="bibr">46</xref>]. 
</p>
